

Paradigm welcomes bene pharmaChem's Dr Christian Reiter to the team.

Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with unmet clinical needs, welcomes Dr Christian Reiter who has joined Paradigm's R&D Department as Senior Principal Research Scientist. Dr. Reiter officially joined the Paradigm team on Monday 15th November.

Dr Reiter has been working as Director of Research and Development with bene pharmaChem GmbH & Co. KG (Bene) for more than 13 years. During his tenure at Bene, Christian developed analytical methods for the chemical characterisation of pentosan polysulfate sodium (PPS) and quantification in biological matrices and worked on potential application of PPS in new indications and the development of second-generation drugs.

Paradigm has a longstanding relationship with Bene, the only FDA approved manufacturer/supplier of PPS. This was highlighted in September 2020 with the extension and expansion of the exclusive license and supply agreement between the companies, and again in March 2021 with the signing of a new collaboration agreement allowing for the further development of injectable pentosan polysulfate sodium (iPPS) and other formulations containing PPS to address unmet needs in new clinical indications (ASX release 31 March 2021).

Paradigm CSO, Dr Ravi Krishnan commented: *"We are very excited to welcome Dr Reiter to Paradigm. Christian's extensive knowledge base and experience with PPS will be great value to Paradigm's R&D projects in developing new pipeline and second-generation products, as well as Paradigm's OA and MPS programs."*

Paradigm CEO, Mr Paul Rennie commented: *"We are delighted Dr Reiter has chosen to join the Paradigm team. His decision reflects the long-standing and strong collaborative relationship between Paradigm and Bene to develop PPS to address unmet needs in new clinical indications."*

Dr Christian Reiter, Paradigm Senior Principal Research Scientist: *"After working alongside many of the Paradigm team over the last 6 years, I have been immensely impressed with the strength and experience of the team, the thorough understanding of PPS and the established pathway to commercialisation for multiple indications with an unmet need. I look forward to continuing work with the Paradigm team to further progress our understanding of the molecule, support clinical activities and build out the pipeline of future indications."*

Dr Reiter has a medical degree from the Ludwig-Maximilians-University (LMU), Munich, and postgraduate qualifications in scientific research from the Institute of Immunology at LMU.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, degenerative disease, infection or genetic predisposition. Paradigm is also investigating proof-of-concept for the use of PPS in respiratory and heart failure indications.

Authorised for release by Paradigm CEO, Mr Paul Rennie

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com